Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Seattle, Washington

Cancer biologic therapy trials in Seattle, WA

74 cancer biologic therapy studies are recruiting participants at sites in Seattle as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Seattle at a glance

  • 74 studies are recruiting at a site in Seattle.
  • By phase: Phase 1 (11), Phase 1/2 (3), Phase 2 (36), Phase 2/3 (1), Phase 3 (22), No phase (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (38), industry (24), government (12).
  • By research area: Lymphoma (35), Lung Cancer (20), Breast Cancer (11), Melanoma (4), Prostate Cancer (3), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Seattle

Basic details from each study's public record (the 30 most recently updated of 74). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT05564377 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Fred Hutchinson Cancer Center ( Site 0042)
    Registry record
    NCT06841354 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Fred Hutchinson Cancer Center ( Site 0069)
    Registry record
    NCT06966700 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06058377 · updated
  5. A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT07112053 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Lung cancer studies recruiting in Seattle

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  3. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT07388524 · updated
  4. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Swedish Cancer Institute ( Site 0143)
    Registry record
    NCT06623422 · updated
  5. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Fred Hutchinson Cancer Center ( Site 3202)
    Registry record
    NCT07513376 · updated
  6. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06096844 · updated
  7. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Swedish Medical Center-Swedish Cancer Institute ( Site 0023)
    Registry record
    NCT07221474 · updated
  8. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Swedish Medical Center
    Registry record
    NCT06646276 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Seattle

  1. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Fred Hutchinson Cancer Research Center · University of Washington · VA Puget Sound Healthcare System
    Registry record
    NCT07164443 · updated
  2. Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT07466498 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Melanoma studies recruiting in Seattle

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Seattle, WA on ClinicalTrials.gov.

Lymphoma studies recruiting in Seattle

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Seattle Children's Hospital
    Registry record
    NCT06317662 · updated
  2. Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Washington
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06784726 · updated
  3. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Seattle Children's Hospital
    Registry record
    NCT06173518 · updated
  4. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    FHCC at Northwest Hospital · Fred Hutchinson Cancer Center · Swedish Medical Center-First Hill
    Registry record
    NCT04269902 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Seattle Children's Hospital
    Registry record
    NCT04546399 · updated
  6. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT04840602 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Seattle Children's Hospital
    Registry record
    NCT05675410 · updated
  8. BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    PeproMene Bio, Inc.
    Study site
    Providence Swedish Cancer Institute
    Registry record
    NCT05370430 · updated
  9. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT06649812 · updated
  10. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT07015242 · updated
  11. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT03150693 · updated
  12. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Swedish Medical Center-First Hill
    Registry record
    NCT05976763 · updated
  13. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study sites
    Fred Hutchinson Cancer Center · Swedish Cancer Institute
    Registry record
    NCT06500273 · updated
  14. Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06839053 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Seattle, WA on ClinicalTrials.gov.

Ask about studies near Seattle

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call